<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602613</url>
  </required_header>
  <id_info>
    <org_study_id>CL4-0001P</org_study_id>
    <nct_id>NCT02602613</nct_id>
  </id_info>
  <brief_title>AMENDTM Mitral Valve Repair System, Annuloplasty Ring Applied in a Transcatheter Method</brief_title>
  <official_title>AMEND I Study - for the Valcare Medical AMEND TM Mitral Valve Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valcare Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valcare Medical Ltd.</source>
  <brief_summary>
    <textblock>
      A multi center study to evaluate the safety of the AMENDTM Mitral Valve Repair System and its&#xD;
      ability to reduce mitral regurgitation. AMEND device is an annuloplasty ring implanted in a&#xD;
      minimally invasive trans-catheter method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Freedom from major SAE's at 30 days following procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from major SAE's at 30 days following procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success of implantation</measure>
    <time_frame>End of procedure</time_frame>
    <description>Ring location and attachment based on echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Freedom from major SAE's at 6 months following procedure</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from major SAE's at 6 months following procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>AMEND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMEND Mitral Valve Repair System</intervention_name>
    <description>Annuloplasty ring applied in a transcatheter method</description>
    <arm_group_label>AMEND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age ≥18&#xD;
&#xD;
          -  The patient requires mitral valve annuloplasty for mitral regurgitation without the&#xD;
             need for concomitant cardiovascular surgical procedures&#xD;
&#xD;
          -  NYHA functional capacity ≥2&#xD;
&#xD;
          -  The subject is high risk to undergo a mitral valve surgery as assessed by the center&#xD;
             heart team&#xD;
&#xD;
          -  The patient is willing to comply with study procedures and is available to return to&#xD;
             the implant center for follow-up visits.&#xD;
&#xD;
          -  The patient is willing to provide Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac or non-cardiac major or progressive disease, which in the investigator's&#xD;
             discretion produces an unacceptable increased risk to the patient.&#xD;
&#xD;
          -  Life expectancy of less than twelve months.&#xD;
&#xD;
          -  Heavily calcified annulus or leaflets.&#xD;
&#xD;
          -  Previous or active endocarditis.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  A previously implanted prosthetic mitral valve or annuloplasty ring/band.&#xD;
&#xD;
          -  The patient is contraindicated to general anesthesia.&#xD;
&#xD;
          -  Pregnant (urine HCG test result positive) or lactating patient.&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
&#xD;
          -  Participation in concomitant research studies of investigational products that will&#xD;
             interfere with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ZNA Middelheim Hospital</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

